pfizer glp-1 news says it will advance once-daily pill after all 2 Companies Poised to Capitalize

Here's what the trials have shown: Phase 1b Trial Results (Lancet 2022) The initial Phase 1b study evaluated retatrutide safety, tolerability, and pharmacokinetics in 72 adults with type 2 diabetes over 12 weeks

Ang R, Mastitskaya S, Hosford PS, et al

reports consulting fees from Metis Therapeutics, outside the submitted work

The move to put coverage back on the table comes after manufacturers, including Novo Nordisk and Eli Lilly, slashed costs in recent months.

Causing fat loss while maintaining muscle mass would therefore be an attractive feature of a novel therapeutic (Versanis bimagrumab may be differentiated here)

Biomedicines 11(11):2990